Canadian-based AbCellera has received a grant from the Bill & Melinda Gates Foundation to help fight tuberculosis.

The grant will be used to discover monoclonal antibodies against mycobacterium tuberculosis (Mtb). 

As part of the project, the company’s antibody discovery platform will be used to generate panels of monoclonal antibodies against ten tuberculosis targets.

New diagnostic tests will be developed using these antibodies for disease caused by Mtb.

AbCellera founding CEO Dr Carl Hansen said: "It is a real honour to have the support of the Bill & Melinda Gates Foundation, and we are grateful for the chance to contribute in the fight against tuberculosis."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"It is a real honour to have the support of the Bill & Melinda Gates Foundation, and we are grateful for the chance to contribute in the fight against tuberculosis."

The company has established a microfluidic single-cell platform using, where several immune cells can be screened in a single day to increase the speed and efficiency of monoclonal antibody discovery from natural immune responses of immunised animals and human patients. 

With AbCellera's technology in place, new avenues open up for human immune profiling, as well as infectious disease research to accelerate the development of diagnostic tests and vaccines that are required immediately.

An estimated nine million new cases of tuberculosis is reported globally each year.

The company stated that the development of low-cost tests with better sensitivity would have major impact in combating the disease spread in low-income to middle-income countries.


Image: Close-up of a Mycobacterium tuberculosis culture revealing the organism’s colonial morphology. Photo: courtesy of CDC / Dr. George Kubica.